Perth , Australia

Institute for Respiratory Health

Cardiovascular Diseases

Cystic Fibrosis

Fibrosis

Pulmonary Fibrosis

Chronic Obstructive Pulmonary Disease

Infections

Respiratory Tract Infections

Pseudomonas Infections

Lung Diseases

Reinfection

RSP-1502

Bisoprolol

Respirion Pharmaceuticals

The George Institute

condition

Communicable Diseases

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Institute for Respiratory Health | Perth , Australia

Site insights

Work at this site?

Active trials

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Trial sponsors